Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Block

Showing results (411-420 of 488) with videos related to

Pageof 49
Sort By:
Arthritis Research & Therapy|August 22, 2012
Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in miceAjay Jain, Henrik S Olsen, Ravi Vyzasatya, et al.
Annals of the Rheumatic Diseases|April 15, 2004
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexateS B Cohen, L W Moreland, J J Cush, et al.
Melanoma Research|August 29, 2024
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital settingRonen Stoff, Svetomir N Markovic, Robert R McWilliams, et al.
Oncoimmunology|June 12, 2020
HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancerYingxue Ren, Yesesri Cherukuri, Daniel P Wickland, et al.
Gynecologic Oncology|May 3, 2017
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancersGerardo Colon-Otero, S John Weroha, Nathan R Foster, et al.
JCO Clinical Cancer Informatics|April 30, 2024
Identification and Characterization of Immune Checkpoint Inhibitor-Induced Toxicities From Electronic Health Records Using Natural Language ProcessingHannah Barman, Sriram Venkateswaran, Antonio Del Santo, et al.
Journal of Autoimmunity|August 24, 2017
Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated diseaseHaoping Sun, Henrik S Olsen, Emmanuel Y Mérigeon, et al.
Oncogene|August 7, 2023
PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interactionUpasana Ray, Prabhu Thirusangu, Ling Jin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 2, 2024
MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor UseStephanie B Syc-Mazurek, Hannah Zhao-Fleming, Yong Guo, et al.
The International Journal of Oral & Maxillofacial Implants|August 17, 2002
Prospective evaluation of implants connected to teethMichael S Block, Denise Lirette, Diana Gardiner, et al.
Pageof 49

Showing results (411-420 of 488) with videos related to

Sort By:
Pageof 49
Arthritis Research & Therapy|August 22, 2012
Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in miceAjay Jain, Henrik S Olsen, Ravi Vyzasatya, et al.
Annals of the Rheumatic Diseases|April 15, 2004
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexateS B Cohen, L W Moreland, J J Cush, et al.
Melanoma Research|August 29, 2024
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital settingRonen Stoff, Svetomir N Markovic, Robert R McWilliams, et al.
Oncoimmunology|June 12, 2020
HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancerYingxue Ren, Yesesri Cherukuri, Daniel P Wickland, et al.
Gynecologic Oncology|May 3, 2017
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancersGerardo Colon-Otero, S John Weroha, Nathan R Foster, et al.
JCO Clinical Cancer Informatics|April 30, 2024
Identification and Characterization of Immune Checkpoint Inhibitor-Induced Toxicities From Electronic Health Records Using Natural Language ProcessingHannah Barman, Sriram Venkateswaran, Antonio Del Santo, et al.
Journal of Autoimmunity|August 24, 2017
Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated diseaseHaoping Sun, Henrik S Olsen, Emmanuel Y Mérigeon, et al.
Oncogene|August 7, 2023
PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interactionUpasana Ray, Prabhu Thirusangu, Ling Jin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 2, 2024
MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor UseStephanie B Syc-Mazurek, Hannah Zhao-Fleming, Yong Guo, et al.
The International Journal of Oral & Maxillofacial Implants|August 17, 2002
Prospective evaluation of implants connected to teethMichael S Block, Denise Lirette, Diana Gardiner, et al.
Pageof 49